Thursday, April 30, 2026
Newsletter About
News & Politics

US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises

Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesityFaced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and…

This article was originally published by The Guardian World and is republished here under license.

Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesity

Faced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and public employees have now started to restrict or eliminate coverage.

The pullback stems from the dramatic increase in public spending on drugs such as Ozempic and Wegovy in recent years.

Continue reading…

More in News & Politics

View All →

Leave a Reply

Discover more from The Meridian Review

Subscribe now to keep reading and get access to the full archive.

Continue reading